|Hospital:||Charing Cross Hospital|
|Patients: This phase II study involved 63 patients with relapsed malignant pleural mesothelioma. Their median age was 59, ranging from 29 to 77 years old. The majority (93.6%) of patients were men.|
Treatment: Patients were treated weekly with the chemotherapy drug vinorelbine.
Toxicity: Grade 3/4 neutropenia was reported in 55% of patients; other, less common grade 3/4 toxicities were anemia, constipation, neuropathy, and phlebitis.
Results: The median overall survival was 9.6 months.
Correspondence: Dr. Justin Stebbing